OBJECTIVES: To find out the occurrence of ovarian hyperstimulation in patients who were hyper responders in vitro fertilization cycles. The secondary outcome was to assess the number of metaphase II oocytes and fertilization rate, cleavage rate, and pregnancy outcome when GnRHa is used for final maturation and triggering ovulation. STUDY DESIGN, SIZE, and DURATION: This is a retrospective descriptive analysis of cases managed at a single center from June 2017 till May 2018. PATIENTS & METHODS: Twenty patients were identified as hyper responders based on the baseline, ovarian reserve characteristics, that is antral follicle count, (AFC) > 25, AMH > 4ng/ml and on the day of trigger, follicles >-25 on a number of = 11mm were administered GnRHa trigger and 1500IU hCG on oocyte retrieval day while luteal phase was supported with daily vaginal progesterone and twice daily estradiol valerate. Sixteen patients underwent fresh transfer while four patients had their embryos frozen. MAIN RESULTS: Twenty patients were identified as high risk and their baseline charmeansristics were, a mean age of 31.7 ± 4.50, mean antral follicle count of 25.7 ± 5.01, Anti Mullerian hormone level mean of 4.64 ± 2.52 and PCOS present in 35% cases. Peak estradiol level means 13455-± 6632pmol/l and mean follicles count of 25.45 ± 8.78 confirmed a high response. The oocyte yield was 11.45+ Metaphase oocyte retrieved was 85.5% and the cleavage rate of 93%. No case of early-onset OHSS was identified. Only one patient developed moderate OHSS. The pregnancy rate was 31.25%. The miscarriage rate was 6.3% and ongoing pregnancy was 25%. CONCLUSION: This small retrospective descriptive analysis supports the view of current literature that GnRH trigger not only prevents early onset OHSS but also achieves an increase of M11 oocytes. In addition, pregnancy outcome is not statistically different to those cycles where hCG is used as a trigger.